Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06421142
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-05-09
Brief Title:
FAPI and FDG PETMRI in Diagnosis and Therapy Prediction of Bladder Cancer
Sponsor:
First Affiliated Hospital of Fujian Medical University
Organization:
First Affiliated Hospital of Fujian Medical University
Study Overview
Official Title:
Application Research of FAPI Positron Emission TomographyPETMRI 18F-Fluorodeoxyglucose FDG PETMRI and MRI in the Diagnosis of Muscular Invasive Bladder Cancer and Evaluation of Neoadjuvant Therapy Efficacy
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this trial is to investigate the value of FAPI PETMRI FDG PETMRI and MRI in diagnosing MIBC and predicting the efficacy of neoadjuvant therapy for MIBC patients so as to guide the clinic to adjust the treatment plan in time and benefit MIBC patients
Detailed Description:
The MIBC diagnostic study was a prospective trial According to the inclusion and exclusion criteria patients with suspected MIBC were enrolled and underwent FAPI PETMRI FDG PETMRI and MRI examination and the imaging data and clinical laboratory and pathologic data were collected and the postoperative pathological results were used as the gold standard to compare the accuracy of FAPI PETMRI FDG PETMRI and MRI in diagnosing MIBC
The MIBC neoadjuvant therapy efficacy assessment study was a prospective trial Patients with MIBC were enrolled according to the inclusion and exclusion criteria the regimen was selected individually according to the patients condition and the indicators were followed up until the end of time or the occurrence of an endpoint event to obtain information on survival time FAPI PETMRI FDG PETMRI and MRI were performed once before the start of neoadjuvant therapy and once after the end of therapy and after the end of neoadjuvant therapy patients received transurethral cystectomy of bladder tumors or radical cystectomy according to the efficacy and condition and the combination of the imaging data and the clinical laboratory and pathological data were used to compare FAPI PETMRI FDG PET MRI and MRI in the assessment of the efficacy of neoadjuvant therapy in MIBC patients to guide clinical treatment options
The MIBC neoadjuvant therapy efficacy assessment study was a prospective trial Patients with MIBC were enrolled according to the inclusion and exclusion criteria the regimen was selected individually according to the patients condition and the indicators were followed up until the end of time or the occurrence of an endpoint event to obtain information on survival time FAPI PETMRI FDG PETMRI and MRI were performed once before the start of neoadjuvant therapy and once after the end of therapy and after the end of neoadjuvant therapy patients received transurethral cystectomy of bladder tumors or radical cystectomy according to the efficacy and condition and the combination of the imaging data and the clinical laboratory and pathological data were used to compare FAPI PETMRI FDG PET MRI and MRI in the assessment of the efficacy of neoadjuvant therapy in MIBC patients to guide clinical treatment options
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None